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Abstract Multiple ablation technologies are used to provide atrial fibrillation therapy during cardiac
surgery. A rigorous search was performed to identify all peer-reviewed papers that provided clinical
outcome data following ablation therapy. A META analysis showed significant differences in clinical
outcome by ablation technology: clinicians, using temperature-controlled RF power delivery, achieved
higher rates of normal sinus rhythmat follow-up, and patients ablatedwithmicrowave ablation had lower
rates of normal sinus rhythm than the average of all ablation-treated patients. Permanent pacemaker
implantation rates were higher than average for patients treated with microwave or argon-based
cryoablation technologies, but were lower than the average for patients treated using temperature-
controlled RF.
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Open access under CC BY-NC-ND license.1. Introduction
Atrial Fibrillation (AF) affects about 3 million people in the
United States and about 5 million people in Europe. In both
regions, the yearly rate of new diagnoses of AF is about 10%
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Open access under CC BY-NC-ND license.of the incidence (e.g. about 300,000 for the US). Because AF
has an increasing prevalence with both increasing age and with
increasing severity of cardiac disease, a significant subset of AF
patients have cardiac surgery each year (about 80,000 in the US,
or about 14 of the incidence of AF). Thus, over time, the cardiac
surgeon could significantly impact AF in Europe and in the US
by treating all cardiac surgery patients with concomitant AF
procedures.
When the only option for concomitant AF procedures
was to add the Cox Maze cut-and-sew procedure to the
primary indicated surgery, few surgeons opted to perform
concomitant AF. However, with the advent of easier-to-use
energy-based, surgical ablation devices, cardiac surgeons are
adopting concomitant AF procedures in increasing numbers.
Increasingly, cardiac surgeons are also minimally performing
procedures focused only on atrial fibrillation therapy in
patients without structural heart disease. As the procedures for
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more accepted, surgeons are seeking objective evidence for
making decisions on which ablation technology to use and on
how to apply that technology. This META analysis provides
information on the clinical outcomes achieved by many
investigators using different ablation technologies.
2. Methods
2.1. Paper identification and selection process
The CTS database was used to locate the great majority of
papers initially reviewed for possible inclusion in the analysis
presented in this paper. We included both online and printed
published papers that were accepted into publication by peer
review; data from abstracts were not used. One set of searches
focused on procedure type, including the following search
terms: Cox Maze, AF surgery and surgical maze. Another set
of searches focused on ablation tools or procedure brand
names, including COBRA, Flex, Cardioblate and CryoMaze.
Other searches that successfully identified references included
searches on AF-focused companies, such as AtriCure, CryoCath
and AFx. PUBMED searches were also employed, but those
searches yielded only about 30 additional papers not found in
the CTS database. Finally, the references cited in the assessed
papers were reviewed to identify any additional papers missed
by the electronic search process. This exhaustive search yielded
more than 200 references.
The META Analysis includes all papers that provided clini-
cal outcomes for ablative treatments provided by commercially
available technologies, which can be classified into the follow-
ing groups:
Group I: RF Ablation with temperature-controlled power
delivery [1–26].
Group II: Monopolar RF ablation without temperature-
controlled power delivery. This group includes sys-
tems with power delivery at a set voltage, current or
power, and systems that shut off RF power, based on
system impedance [27–48].
Group III: Ablation using microwave [49–60].
Group IV: Bipolar RF ablation with clamping technology. In
this group, impedance or temperature was used
to modify RF power delivered to the tissue, or to
terminate RF power [61–78].
Group V: Cryoablation based on extreme cooling attained by
expanding argon gas [79–84].
Group VI: Ablation using High Intensity Focused Ultrasound
(HIFU) [85–87].
We excluded all papers that used none of the technologies
in the selected groups or that used two or more of those
technologies. We also excluded all papers describing outcomes
for 10 or fewer patients, because of concerns about the learning
curve and patient selection bias issues. This exclusion had
almost no effect on the statistical power of our analyses. We
also excluded several references that failed to provide data in
a manner that we needed for our META analysis (e.g. if it was
not possible to extract actual numbers of patients evaluated
at a given time point). One reference was eliminated because
another paper reported on the same patient data set (the data
were consistent in the twopapers). Table 1 shows thenumber of
papers and patient outcomes used as input to theMETA analysis
for each of the six technologies.2.2. Definition of surgical ablation success
Wedefined percentage therapeutic success, for patients that
had documented AF prior to surgery, as the percentage of pa-
tients in Normal Sinus Rhythm (NSR) after surgical AF ther-
apy, without any additional invasive rhythm therapy. Patients
treated by an EP procedure for any atrial tachyarrhythmia (gen-
erally, AF; right atrial flutters or left atrial flutters, but including
focal atrial tachyarrhythmias as well) following surgery were
placed in the therapy failure group at all evaluation time points
following the EP procedure. Furthermore, patients treated by
a second cardiac surgical procedure, such as Cox III Maze, fol-
lowing an initial surgical ablation procedure, were placed in the
therapy failure group at all evaluation time points following the
second surgical AF procedure. Patients not treatedwith a device
from a particular technology group because of an ablation de-
vice failure, were placed in the therapeutic failure group for that
technology at all evaluation time points. Patients getting pace-
makers or defibrillators in the hospital, following the ablation
procedure or within the first 30 days of surgery, were placed in
the therapy failure group at all evaluation time points, unless
the implant was planned prior to the ablative therapy.
There were many categories of clinical outcome data that
were not used in our definition of success. Most notable is
patient use of antiarrhythmic drugs. The authors are well
aware of the current recommendations of the Heart Rhythm
Society/STS guidelines to report such data. However, fewpapers
reported patient use of antiarrhythmic drugs in both success
and failure groups. Thus, reporting on NSR rates, without drugs,
was not feasible for this report. Right or left atrial functions
were not used to define ablative success, even when reported.
According to the new Heart Rhythm Society/STS guidelines,
no person that is being considered for further AF treatment
should be considered to be in permanent AF. Instead, patients
that have been in AF continuously should be classified as
being long-standing persistent AF patients. Thus, in the spirit of
the current Heart Rhythm Society/STS guidelines for reporting
treatment success, no patientwas classified as irreversibly in AF
(i.e. in permanent AF), if treatment continued after a detected
episode of AF. Thus, the outcome for a patient known to be in
AF at 6 months post surgery, but in continuous normal sinus
rhythm at 12months, was considered a failure at 6 months, but
a success at 12 months.
2.3. Evaluation of rhythm status
Because reliable preoperative assignment of patients into
classes of persistent AF versus permanent AF (now classified
as longstanding persistent) was not possible from the data
presented inmost papers, these two groupswere combined and
labeled as non-paroxysmal, and were compared to paroxysmal
AF patients.
Paroxysmal AF patients required a 24 h Holter rhythm
or its equivalent to establish that patients experiencing
tachyarrhythmias following surgery were in NSR at a given
evaluation time point (e.g. patients in AF at the three-month
evaluation time were classified as in AF at the 6-month time
point if the only evidence of 6-monthNSR statuswas an isolated
ECG strip).
Non-paroxysmal AF patients required a 12-lead ECG (and to
be free of AF symptoms) to establish that patients experiencing
tachyarrhythmias following surgery were in NSR at a given
evaluation time point (e.g. patients in AF at the three-month
evaluation time were classified as in AF at the 6-month time
point if there was no documented ECG evidence of NSR at 6
months).
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Technology Number of publications Number of patients Percent paroxysmal (%)
RF with temperature 26 1731 13*
RF with no temperature 22 1453 24
Microwave 12 592 10*
Bipolar 18 1256 39**
CRYO 6 331 33**
HIFU 3 235 38**
Averages (all technologies) 87 5596 24
* Significantly lower than average.
** Significantly higher than average.2.4. Assumptions used to calculate NSR rates when data were
missing from papers
Outcome data used in META analysis was sometimes
incomplete in the papers used for the META analyses reported
herein. The most common issues relate to pacemaker implant
rates and its influence on patient outcomes. Most papers
report an overall pacemaker implantation rate, but give no
information on the number of pacemakers in the reported ‘‘AF-
free’’ group or the ‘‘AF’’ group. In those cases, we assume that
the pacemaker implantation rate was the same in both groups.
The number of curative EP procedures or the number
of pacemaker implants following surgery is often reported
without an indication of the timing of each of these procedures.
In these cases, we assume that the EP procedures or pacemaker
implant procedures occur early in the follow-up periods. The
number of patients evaluated at each post-opmilestone (e.g. 6-,
12- and 24-month follow-up) is often provided, but the rate
of pacemaker implantation or EP procedure history of the
actual patients included in eachmilestone follow-up time is not
provided. In those cases, the percentage of patients treatedwith
pacemakers or EP ablation procedures was assumed to be equal
at all rhythm evaluation time points (e.g. if 4 of 50 total patients
had EP ablation during the evaluation period, but timing was
not defined, thenwe assumed that 4/50 or 8% of the 22 patients
studied at one year post-op were surgical failures).
2.5. Statistical methods used
All data subjected to META analysis are categorical data
and are presented in contingency tables. Chi Squared analysis
was used to determine if the patient outcomes were different
among the patients treated with the six technologies. If this
test indicated that the outcomes (e.g. NSR rates) were not
the same, then a Fischer Exact Test was done, comparing the
outcomes achieved with each particular technology to the
outcomes achievedwith all other technologies. Since 5 or 6 such
comparisons were made, only p values<0.01 were considered
significant. The results from these analyses are presented in
tables.
3. Results
Chi Squared analysis showed that there were highly
significant differences in the success rates among all AF patients
treated with the six technologies (Table 2). The Fischer Exact
Test identified one technology with higher success rates than
the average result (RF with temperature control) and one with
significantly lower success rates (microwave). CRYO, HIFU,
bipolar RF andmonopolar RFwithout temperature controlwere
not different from the averages outcome. We also redid the
statistical analysis, excluding microwave technology, since it is
currently commercially unavailable. In that analysis, RF withtemperature control had higher success rates than the average
result, and the success rates for the other fourwere not different
from average.
In some studies of clinical outcomes of surgical AF therapy,
investigators have reported that success is higher for paroxys-
mal patients. Since the percent of patients in paroxysmal AFwas
significantly different among ablation technologies (Table 1),
we also completed additional META analyses on the subsets of
non-paroxysmal patients (Table 3) and of paroxysmal patients
(Table 4). The microwave papers reported few separate results
by AF types, so the success rates for only 5 technologies were
compared for the subsets of paroxysmal and non-paroxysmal
patients.
Non-paroxysmal patients treated with ablation devices
using RF with temperature control had significantly better
success rates than average, and those treated with microwave
or bipolar had lower success rates than average. For paroxysmal
patients, all technologies provided statistically the same success
rates. A comparison of the success rates for patients treated
with all technologies shows that the reported success rates
for paroxysmal patients are higher than for non-paroxysmal
patients, with a highly statistically significant confidence
level. In addition, the success rates for all technologies were
significantly better for paroxysmal AF patients than for non-
paroxysmal patients (Table 5).
Chi Squared analysis showed that there were significant dif-
ferences in the pacemaker implantation rates among patients
treated with the six technologies (Table 6). The Fischer Exact
Test identified one technology with a lower pacemaker im-
plantation rate than the average result (RF with temperature
control), and two with significantly higher implantation rates
(microwave and CRYO). HIFU, Bipolar RF and monopolar RF
without temperature control were not different from the aver-
ages of all other technologies.
4. Discussion
Our META analysis showed highly statistically significant
different outcomes for surgical AF therapy when different
ablation technologies were used. These differences could result
from differences in the patient populations studied, differences
in the lesion sets that can be created by the different ablation
technologies and differences in the lesion-making effectiveness
of the different technologies. It is quite clear from Table 1,
that the patient population differed significantly among the
sets of patients studied using the different technologies.
Specifically, the percentage of paroxysmal patients treated
with the different technologies differed greatly among the
technologies studied. However, repeating theMETA analysis on
the subset of patients identified as non-paroxysmal showed no
changes in the technologieswith higher treatment success rates
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AF types treated.
Technology all patients AF surgical success rates all AF patients
N 6 months %NSR N 1 year %NSR
RF with temperature 586 80** 709 79*
RF with no temperature 737 69 909 72
Microwave 494 59* 110 55*
Bipolar 497 71 493 72
CRYO 211 77 136 73
HIFU 229 74 84 70
Averages (all technologies) 2754 71 2441 73
* Significantly lower than average.
** Significantly better than average.Table 3: Percentage of successful outcomes for non-paroxysmal AF patients at 6 and 12 months following the index procedures achieved by each of
the six technologies.
Product non-paroxysmal AF patients AF surgical success rates non-paroxysmal AF patients
N 6 months %NSR N 1 year % NSR
RF with temperature 361 77** 474 76**
RF with no temperature 553 69 534 72
Microwave 360 54* 110 55*
Bipolar 165 64* 137 64*
HIFU 136 68 34 68
Averages (all technologies) 1633 67 1323 71
* Significantly lower than average.
** Significantly better than average.Table 4: Percentage of successful outcomes for paroxysmal AF patients at 6 and 12 months following the index procedures achieved by each of five
technologies.
Product paroxysmal AF patients AF surgical success rates paroxysmal AF patients
N 6 months %NSR N 1 year % NSR
RF with temperature 46 91 40 93
RF with no temperature 39 85 51 78
Bipolar 74 80 80 89
HIFU 57 82 21 76
Averages (all technologies) 216 84 192 78
∗ Significantly lower than average.
∗∗ Significantly better than average.Table 5: Comparison of success rates in paroxysmal versus non-paroxysmal patients at 12 months achieved by four technologies.
Product AF surgical success rates at 12 months
Paroxysmal AF Non-paroxysmal AF
N % NSR N % NSR
RF with temperature 40 93 474 76**
RF with no temperature 51 78 553 72
Bipolar 80 89 137 64*
HIFU 21 76 34 68
Averages (all technologies) 192 78 1213 72
* Significantly lower than average.
** Significantly better than average.Table 6: Pacemaker implantation rates for the six ablation technologies.
Technology Pacemaker implantation rate (%)
RF with temperature 2.2*





Averages (all technologies) 6.6
* Significantly lower than average.
** Significantly higher than average.
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analyses using all patients. In both cases, RF with temperature
control had higher success rates, and both microwave and
bipolar had lower success rates than average.
It is interesting to note that for paroxysmal patients, bipolar
ablation has a success rate that is not inferior to the average
rate for all technologies, whereas the results are clearly inferior
for chronic patients. In fact, the difference in success rates
between paroxysmal and non-paroxysmal patients was larger
for this technology than for any other. One possible explanation
for the better relative performance of this technology, when
treating paroxysmal AF patients compared to non-paroxysmal
patients, relates to the more limited lesion set often used with
this technology. If this is the correct explanation for these
results, then these results re-enforce the concept that a more
complete lesion set is especially important for persistent and
long-standing persistent AF patients, as has been previously
reported in individual series by other authors.
Our META analysis results are at least suggestive that
lesion-making effectiveness varies by the type of ablation
technology. Finding such technological differences is not
surprising, since these technologies have been commercially
introduced relatively recently. The first commercial ablation
devices designed to treat AF surgically were introduced just
over 10 years ago. Since then, a number of different devices
have been developed to enable surgeons to treat AF surgically.
To better understand why such differences among the devices
may exist, it is useful to understand how these devices create
lesions.
All currently available ablation devices use temperature
extremes to create lesions. Most systems apply energy to the
target tissue to heat it; wherever tissue temperature exceeds
50 °C,myocytes are killed. If Cryo probes are used,myocytes are
killedwhen local temperatures reach below−40 °C.Whichever
ablative device is used, the affected electrically responsive
tissue is replaced by non-responsive tissue (scar tissue), which
blocks conduction. Thus, all energy-based surgical ablative
treatments for the treatment of atrial fibrillation attempt to
provide lines of conduction block in the atrial tissue, without
the need to cut the tissue and sew it back together. The effective
ablative treatments create a permanent conduction block by
the same mechanism as the cut-and-sew technique: a scar is
eventually formed that forms a line of block across the entire
thickness of the atrial wall.
For heat-generating ablation technologies, the size and
shape of the lesion created are defined by the volume of tissue
heated to 50 °C and above. Expressed in another way, the 50 °C
isotherm forms the boundary of the lesion created by such
technologies. For normothermic patients, this corresponds to a
13 °C increase in local tissue temperature. For safety reasons,
none of the heated tissue should be heated to above 100 °C,
since the steam so created can disrupt the tissue, or even
cause an atrial wall perforation. The RF andmicrowave ablation
technologies require the direct contact of the ablating devices
with the tissue, and each create lesions slightly longer than
the length of the ablation device. The created lesions have
a semicircular cross-section that can vary in size somewhat
along the linear extent of the lesion. Both energy sources are
capable of creating lesions 6–8mmdeep into thick tissue, using
applied power times of 60–120 s. However, the effectiveness
of these technologies in creating lesions varies with tissue
contact pressure and the type of tissue directly contacting the
ablation devices. Because overheating the tissue causes serious
safety problems, ablation technologies, using fixed-parametersto ablate tissue for treating atrial fibrillation, use settings that
create lesions only 4–5 mm in depth. Since the atrial wall is
typically 2–5 mm, such an approach can often achieve full
width lesions, but gaps in the lesion line, where the tissue
is a little wider, are also common. When using temperature
controlled ablation, power delivery is determined by local
tissue temperatures: thicker tissues heat up more slowly than
thin tissues, resulting in higher total energy delivery to the
thicker tissue, as required to better assure full thickness lesions.
Conversely, energy delivery to thin tissue is constrained in
order to maintain a safe range of temperatures in the thin
tissue. Since safety is the most important design constraint for
ablation devices, technologies using fixed parameter ablation
can result in ablation designs that are ineffective under some
operating conditions. One design strategy that addresses this
issue is to use local surface temperature to control energy
delivery to the tissue. This approach enables more aggressive
applications of energy to heat tissue, while avoiding potentially
dangerous overheating situations. The superior results with the
technology using RF heating with temperature control tend to
validate that approach to the design of the ablation device.
Lesions are created quickly by bipolar RF devices, resulting in
lesions that are primarily created by energy deposition during
the ablating process, and thermal spread is of less importance
to lesion formation thanwithmost other ablation technologies.
The cross-section of the lesions made using this technology
is long and narrow; with the longest dimension of the cross-
section being the width of the tissue. The length of the lesion
so created is generally equal to, or slightly longer than, the
length of the electrode contacting the tissue. The transmural
lesion is widest near the midpoint between the jaws applying
the RF current, but thatmid-pointwidth is reduced to zero,with
tissue surviving in between the jaws for lesions that are not
adequately formed.
RF bipolar ablation is the most widely applied technology
in use today for surgical AF therapy. Properly designed bipolar
ablation devices can achieve reliable transmural epicardial
lesions that isolate pulmonary veins. However, as our META
analysis shows, clinical results with this type of technology
appear to produce inferior success rates for AF therapy applied
to patients with non-paroxysmal AF. The technology suffers
from a limited lesion set that can be achieved off bypass, and
some versions of the bipolar device do not appear to create
reliable isolation of pulmonary veins in patients, at least for
single or double RF power applications. For example, three
clinical papers report that, on average, more than two bipolar
RF ablation applications were required to achieve an acute
conduction block of the right pulmonary veins, and more than
two bipolar RF ablation applications were required to achieve a
conduction block in the left pulmonary veins [68,88,89].
Our META analysis showed remarkably large differences
in pacemaker implantation rates for patients treated with
different ablation technologies: from a low of 2.2% for patient
treated with devices using RF with temperature control, to
the very high pacemaker implantation rates of 17.2% for
patients treated with microwave technology, and 13.5% for
those treated with Cryo ablation. Authors reporting the high
pacemaker implantation rates cite a number of possible reasons
for these high rates, including (1) sick sinus diseases may
have been masked by long-standing persistent AF in some
patients and (2) overly aggressive beta-blocking medication to
limit ventricular tachycardia may have resulted in ventricular
bradycardiawhen patients converted to a regular atrial rhythm.
However, the META results presented in this paper tend to
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implantation rate for ablation devices using RF with and
without temperature control had a higher percentage of non-
paroxysmal AF patients in their treatment groups than the
Cryo ablation group, but both RF groups had a reported
pacemaker implantation rate more than 50% lower than the
Cryo groups. A more likely explanation for the increased
pacemaker implantation rates for the Cryo ablation group is
related to the ablation technology itself: the very wide lesions
created by the argon Cryo system have an increased chance for
affecting the three small epicardial arteries supplying blood to
the SAnode, and thewideCryo lesions have an increased chance
of damaging the AV node.
5. Conclusion
Since temperature extremes are the mechanism by which
ablation lesions are formed, it is perhaps not surprising that
the use of tissue temperature to control the ablation process
provides better clinical outcomes than uncontrolled technolo-
gies, with temperature controlled technology providing better
cure rates and lower complication rates. Technologies with less
monitoring and control of the ablative process suffered with
higher than average complication rates (such was the case for
cryoablation), or had a poorer cure rate, as seenwithmicrowave
technology.
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